Mathematical modeling of postmenopausal osteoporosis and its treatment by the anti-catabolic drug denosumab

被引:53
作者
Scheiner, S. [1 ]
Pivonka, P. [2 ]
Smith, D. W. [3 ]
Dunstan, C. R. [4 ]
Hellmich, C. [1 ]
机构
[1] Vienna Univ Technol, Inst Mech Mat & Struct, A-1040 Vienna, Austria
[2] Univ Melbourne, Australian Inst Musculoskeletal Sci, Melbourne, Vic 3010, Australia
[3] Univ Western Australia, Fac Engn Comp & Math, Nedlands, WA 6009, Australia
[4] Univ Sydney, Sch Aerosp Mech & Mech Engn, Sydney, NSW 2006, Australia
基金
澳大利亚研究理事会; 欧洲研究理事会;
关键词
bone remodeling; pharmacokinetics; systems biology; micromechanics; HUMAN MONOCLONAL-ANTIBODY; BONE-MINERAL DENSITY; KAPPA-B LIGAND; RECEPTOR ACTIVATOR; MECHANICAL STRAIN; MULTIPLE-MYELOMA; SYSTEM-ANALYSIS; WOMEN; CELLS; ALENDRONATE;
D O I
10.1002/cnm.2584
中图分类号
R318 [生物医学工程];
学科分类号
100103 [病原生物学];
摘要
Denosumab, a fully human monoclonal antibody, has been approved for the treatment of postmenopausal osteoporosis. The therapeutic effect of denosumab rests on its ability to inhibit osteoclast differentiation. Here, we present a computational approach on the basis of coupling a pharmacokinetics model of denosumab with a pharmacodynamics model for quantifying the effect of denosumab on bone remodeling. The pharmacodynamics model comprises an integrated systems biology-continuum micromechanics approach, including a bone cell population model, considering the governing biochemical factors of bone remodeling (including the action of denosumab), and a multiscale micromechanics-based bone mechanics model, for implementing the mechanobiology of bone remodeling in our model. Numerical studies of postmenopausal osteoporosis show that denosumab suppresses osteoclast differentiation, thus strongly curtailing bone resorption. Simulation results also suggest that denosumab may trigger a short-term bone volume gain, which is, however, followed by constant or decreasing bone volume. This evolution is accompanied by a dramatic decrease of the bone turnover rate by more than one order of magnitude. The latter proposes dominant occurrence of secondary mineralization (which is not anymore impeded through cellular activity), leading to higher mineral concentration per bone volume. This explains the overall higher bone mineral density observed in denosumab-related clinical studies. Copyright (c) 2013 John Wiley & Sons, Ltd.
引用
收藏
页码:1 / 27
页数:27
相关论文
共 88 条
[1]
Alon U, 2007, INTRO SYSTEMS BIOL D
[2]
[Anonymous], 1998, Skeletal tissue mechanics
[3]
[Anonymous], 2002, Mathematical biology, Interdisciplinary applied mathematics
[4]
A CONTINUOUS WAVE TECHNIQUE FOR THE MEASUREMENT OF THE ELASTIC PROPERTIES OF CORTICAL BONE [J].
ASHMAN, RB ;
COWIN, SC ;
VANBUSKIRK, WC ;
RICE, JC .
JOURNAL OF BIOMECHANICS, 1984, 17 (05) :349-361
[5]
Atkins P. W., 1978, Physical Chemistry
[6]
Time sequence of secondary mineralization and microhardness in cortical and cancellous bone from ewes [J].
Bala, Yohann ;
Farlay, Delphine ;
Delmas, Pierre D. ;
Meunier, Pierre J. ;
Boivin, Georges .
BONE, 2010, 46 (04) :1204-1212
[7]
A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women [J].
Bekker, PJ ;
Holloway, DL ;
Rasmussen, AS ;
Murphy, R ;
Martin, SW ;
Leese, PT ;
Holmes, GB ;
Dunstan, CR ;
DePaoli, AM .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (07) :1059-1066
[8]
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis [J].
Black, DM ;
Greenspan, SL ;
Ensrud, KE ;
Palermo, L ;
McGowan, JA ;
Lang, TF ;
Garnero, P ;
Bouxsein, ML ;
Bilezikian, JP ;
Rosen, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (13) :1207-1215
[9]
A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer [J].
Body, JJ ;
Facon, T ;
Coleman, RE ;
Lipton, A ;
Geurs, F ;
Fan, M ;
Holloway, D ;
Peterson, MC ;
Bekker, P .
CLINICAL CANCER RESEARCH, 2006, 12 (04) :1221-1228
[10]
The mineralization of bone tissue: a forgotten dimension in osteoporosis research [J].
Boivin, G ;
Meunier, PJ .
OSTEOPOROSIS INTERNATIONAL, 2003, 14 (Suppl 3) :S19-S24